Insulet Corporation
No mega hedge funds in our coverage currently report a major 13F position in this stock
Coverage: 0.0%
-
Based on SEC 13F filings
🚀PODD SGDC Quant Rating & Setup
📌 Business Moat Summary:Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
📈8-Quarter Institutional Ownership Evolution
Historical trajectory of institutional holders and allocation weight across the last 8 quarters
🏛️Institutional Investors Holding this Stock
Examine each hedge fund holding this ticker, weight, shares, and recent action
| Manager / Fund | Fund AUM | Weight | Shares Held | Action | Action |
|---|---|---|---|---|---|
| No tracked mega hedge funds currently hold this stock. | |||||
Want to see Wall Street's Top 50 Consensus Buys?
Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.
⚡Planning to trade PODD?
Add this symbol to your private journal or dividend tracker to monitor institutional moves.